5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes

被引：89

作者：

Pardini, Barbara ^{[1
]}

Kumar, Rajiv ^{[2
]}

Naccarati, Alessio ^{[1
]}

Novotny, Jan ^{[3
]}

Prasad, Rashmi B. ^{[2
]}

Forsti, Asta ^{[2
,4
]}

Hemminki, Kari ^{[2
,4
]}

Vodicka, Pavel ^{[1
]}

Bermejo, Justo Lorenzo ^{[2
,5
]}

机构：

[1] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic

[2] German Canc Res Ctr, Div Mol Genet Epidemiol, Heidelberg, Germany

[3] Charles Univ Prague, Fac Med 1, Prague, Czech Republic

[4] Lund Univ, Clin Res Ctr, Ctr Primary Hlth Care Res, Malmo, Sweden

[5] Univ Heidelberg Hosp, Inst Med Biometry & Informat, Heidelberg, Germany

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 72卷 / 01期

关键词：

GENE POLYMORPHISMS; DNA-DAMAGE; FLUOROURACIL; CYTOTOXICITY; RESISTANCE; MECHANISMS; CELLS;

D O I：

10.1111/j.1365-2125.2010.03892.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：162 / 163

页数：2

共 50 条

[1] IDENTIFICATION OF PHARMACOGENOMIC MARKERS OF 5-FLUOROURACIL-BASED CHEMOTHERAPY IN COLORECTAL CANCER
Mini, Enrico
Nobili, Stefania
Napoli, Cristina
Landini, Ida
Morganti, Maria
Cianchi, Fabio
Valanzano, Rosa
Tonelli, Francesco
Mazzei, Teresita
ANNALS OF ONCOLOGY, 2009, 20
[2] Lactose Intolerance Associated With Adjuvant 5-Fluorouracil-Based Chemotherapy for Colorectal Cancer
Osterlund, Pia
Ruotsalainen, Tarja
Peuhkuri, Katri
Korpela, Riitta
Ollus, Anneli
Ikonen, Minna
Joensuu, Heikki
Elomaa, Inkeri
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (08) : 696 - 703
[3] Phenytoin toxicity in a patient receiving 5-fluorouracil-based chemotherapy for metastatic colorectal cancer
Kuruvilla, Sara M.
Mukherjee, Som D.
CURRENT ONCOLOGY, 2011, 18 (06) : 264 - 265
[4] Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy
Chiara, S
Nobile, MT
Vincenti, M
Lionetto, R
Gozza, A
Barzacchi, MC
Sanguineti, O
Repetto, L
Rosso, R
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (04) : 336 - 340
[5] Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy
Silvana Chiara
Maria Teresa Nobile
Maura Vincenti
Rita Lionetto
Alberto Gozza
Maria Cristina Barzacchi
Ornella Sanguineti
Lazzaro Repetto
Riccardo Rosso
Cancer Chemotherapy and Pharmacology, 1998, 42 : 336 - 340
[6] Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy
Catalano, Calogerina
da Silva Filho, Miguel I.
Jiraskova, Katerina
Vymetalkova, Veronika
Levy, Miroslav
Liska, Vaclav
Vycital, Ondrej
Naccarati, Alessio
Vodickova, Ludmila
Hemminki, Kari
Vodicka, Pavel
Weber, Alexander N. R.
Foersti, Asta
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 30 (08) : 838 - 842
[7] Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy
Watson, Roshawn G.
Muhale, Filipe
Thorne, Leigh B.
Yu, Jinsheng
O'Neil, Bert H.
Hoskins, Janelle M.
Meyers, Michael O.
Deal, Allison M.
Ibrahim, Joseph G.
Hudson, Michael L.
Walko, Christine M.
McLeod, Howard L.
Auman, James T.
EUROPEAN JOURNAL OF CANCER, 2010, 46 (18) : 3358 - 3364
[8] SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer
Boulay, JL
Mild, G
Lowy, A
Reuter, J
Lagrange, M
Terracciano, L
Laffer, U
Herrmann, R
Rochlitz, C
BRITISH JOURNAL OF CANCER, 2002, 87 (06) : 630 - 634
[9] SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer
J-L Boulay
G Mild
A Lowy
J Reuter
M Lagrange
L Terracciano
U Laffer
R Herrmann
C Rochlitz
British Journal of Cancer, 2002, 87 : 630 - 634
[10] DcR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer
Mild, G
Bachmann, F
Boulay, JL
Glatz, K
Laffer, U
Lowy, A
Metzger, U
Reuter, J
Terracciano, L
Herrmann, R
Rochlitz, C
INTERNATIONAL JOURNAL OF CANCER, 2002, 102 (03) : 254 - 257

← 1 2 3 4 5 →